Abstracts tagged "gout"

Abstract Number: 0680 • ACR Convergence 2021
Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
N Lawrence Edwards¹, Brian LaMoreaux², Joseph Vitriol³ and Adam Magerman³, ¹University of Florida College of Medicine, Gainesville, FL, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics, Deerfield, IL
Background/Purpose: Pegloticase is FDA-approved for uncontrolled gout and effectively lowers uric acid levels by conversion of circulating uric acid to allantoin, which is readily removed…
Abstract Number: 1573 • ACR Convergence 2021
Vascular Monosodium Urate Crystal Deposition in Gout: A Dual-energy CT and Microscopy Study of Cadaveric Donors
Nicola Dalbeth¹, Mariam Alhilali¹, Peter Riordan¹, Ravi Narang¹, Ashika Chhana¹, Sue McGlashan¹, Anthony Doyle¹ and MARIANO ANDRES², ¹University of Auckland, Auckland, New Zealand, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: Cardiovascular disease is a common comorbidity in people with gout. A hypothesized link between cardiovascular disease and gout is the deposition of monosodium urate…
Abstract Number: 0663 • ACR Convergence 2021
Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout
Quint Soto¹, Alison Petro¹, Bryant England¹, Harlan Sayles¹, Lindsay Helget¹, Punyasha Roul¹, Tuhina Neogi², James O'Dell¹, Brian LaMoreaux³ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Gout is associated with a number of comorbidities such as diabetes that are known risk factors for peripheral vascular disease. These comorbidities along with…
Abstract Number: 0681 • ACR Convergence 2021
Assessing Patterns of Inpatient Gout Management: Pathway for Optimal Patient Treatment Outcomes
Evan Dombrosky¹, Yashswee KC², Joshua Gavin³, Youssef Roman³ and Nehal Shah³, ¹Virginia Commonwealth University Health System, Glen Allen, VA, ²Loyola University, Oak Park, IL, ³Virginia Commonwealth University Health System, Richmond, VA
Background/Purpose: Gout is the most common inflammatory arthropathy worldwide. Despite having evidence-based guidelines, inconsistent management approaches remain a significant barrier to adequate treatment and prevention.…
Abstract Number: 1574 • ACR Convergence 2021
Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography
Rachael Flood¹, Aamir Saeed², Kate Harrington¹, Conor Shortt¹, Ronan Mullan¹ and David Kane¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Worcestershire Acute Hospitals NHS Trust., Worcester, United Kingdom
Background/Purpose: The diagnostic gold standard for gout remains aspiration and identification of monosodium urate (MSU) crystals under polarised light microscopy. Joint aspiration is invasive and…
Abstract Number: 0664 • ACR Convergence 2021
Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study
Jeremy Holyer¹, William Taylor², Angelo Gaffo³, Graham Hosie¹, Anne Horne¹, Borislav Mihov¹, Isabel Su¹, Gregory Gamble¹, Nicola Dalbeth¹ and Sarah Stewart¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago Wellington, Auckland, New Zealand, ³University of Alabama at Birmingham Medical Centre, Birmingham, AL
Background/Purpose: Several factors contribute to the patient experience of gout flares, including pain intensity, duration, frequency, and disability. It is unknown which of these factors…
Abstract Number: 0682 • ACR Convergence 2021
Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
Jasvinder Singh¹ and N Lawrence Edwards², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Florida College of Medicine, Gainesville, FL
Background/Purpose: To assess gout management during the COVID-19 pandemic since September 2020.Methods: We assessed urate-lowering therapy (ULT) use, healthcare utilization, gout-specific health-related quality of life…
Abstract Number: 1575 • ACR Convergence 2021
Urate Crystals Regulate a Distinct JNK-Dependent Metabolic and Inflammatory Response
Anyan Cheng¹, Isidoro Cobo¹, Jessica Murillo Saich¹, Roxana Coras², Alyssa Torres³, Addison Lana¹, Johannes Schlachetzki¹, Ru Liu Bryan⁴, Robert Terkeltaub⁵, Elsa Sanchez-Lopez³, Christopher Glass¹ and Monica Guma⁶, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³University of California San Diego, San Diego, CA, ⁴University of California San Diego and VASDHS, San Diego, CA, ⁵VA/UCSD, San Diego, CA, ⁶University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Although metabolic reprograming and its regulation in macrophages after TLR activation is well established, little is known about the regulation and the role of…
Abstract Number: 0665 • ACR Convergence 2021
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
Abdul Abdellatif¹, Lin Zhao², Paul M. Peloso³, Katya Cherny², Brad Marder², John D. Scandling⁴ and Kenneth Saag⁵, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics plc, Gurnee, IL, ⁴Stanford Medicine, Department of Nephrology, Stanford, CA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and is a…
Abstract Number: 0991 • ACR Convergence 2021
Does Diet Affect Gout Risk Differently Among Genetically Predisposed Women?: Prospective Female Cohort Study Findings over 34 Years
Chio Yokose¹, Natalie McCormick², Na Lu³, Amit Joshi² and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout has long been considered a male disease. However, several recent analyses of the Global Burden of Disease (GBD) Study report a disproportionate worsening…
Abstract Number: 1576 • ACR Convergence 2021
Development of a Plain Radiographic Scoring System for New Bone Formation in Gout
Chang-Nam Son¹, Ken Cai², John Ferrier³, Yun-Jung Tsai³, Thomas Bardin⁴, Anthony Doyle⁵ and Nicola Dalbeth⁵, ¹Keimyung University School of Medicine, Daegu, Republic of Korea, ²University of Auckland, Sydney, Australia, ³Department of Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Hôpital Lariboisiere, Paris, France, ⁵University of Auckland, Auckland, New Zealand
Background/Purpose: Features of new bone formation (NBF) such as sclerosis and spurs are common on plain radiography in tophaceous gout. While a plain radiographic damage…
Abstract Number: 0666 • ACR Convergence 2021
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
Mark Russell¹, Benjamin Ellis², Benjamin Clarke¹, Deepak Nagra¹ and James Galloway³, ¹King's College London, London, United Kingdom, ²Imperial College Healthcare NHS Trust, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: Hospital admissions for gout flares have increased dramatically in recent years. Strategies to reduce hospitalizations and improve uptake of urate-lowering therapy (ULT) are needed.…
Abstract Number: 1000 • ACR Convergence 2021
Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages
Huaping Qin¹, Patricia Oliveira¹, Tiffany Yan¹, Robert Terkeltaub² and Ru Liu Bryan³, ¹University of California San Diego, La Jolla, CA, ²VA/UCSD, San Diego, CA, ³University of California San Diego and VASDHS, San Diego, CA
Background/Purpose: CD38 can function as a degrading enzyme of nicotinamide adenine dinucleotide (NAD), a critical metabolic intermediate serving as enzyme cofactor in redox reactions and…
Abstract Number: 1577 • ACR Convergence 2021
Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout
Adela Navratilova¹, Veronika Voclonová², Hana Hulejová², Lucie Andrés Cerezo¹, Markéta Pavlíková³, Viktor Bečvář², Jakub Zavada¹, Karel Pavelka⁴, Ladislav Senolt⁴ and Blanka Stiburkova⁵, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: IL-37 is an anti-inflammatory cytokine, member of IL-1 family, related to inflammatory and autoimmune diseases. Here we aimed to investigate the association of genetic…
Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Silvia Ruiz-Simón¹, Irene Calabuig², Miguel Gómez-Garberí³ and MARIANO ANDRES⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital General Universitario de Alicante, Alicante, Spain, ³Hospital Universitario San Juan de Alicante, San Juan de Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].